Crispr Therapeutics shares tumble after significant earnings miss
Tilray Brands (NASDAQ:TLRY) President and CEO Simon Irwin D. Simon purchased 165,000 shares of the company’s common stock on July 30, 2025. The purchase comes as the stock trades near $0.61, down about 70% over the past year, though showing strong returns in recent months according to InvestingPro data. The shares were bought at a price of $0.6067, for a total transaction value of $100,105.
Following the transaction, Simon directly owns 3,941,633 shares of Tilray Brands.
In other recent news, Tilray Inc . reported its fourth-quarter 2025 financial results, revealing a mixed performance. The company achieved earnings per share of $0.02, surpassing the analyst forecast of -$0.02. However, Tilray’s revenue fell short of expectations, coming in at $224.5 million compared to the projected $247.02 million, resulting in a 9.12% miss. Jefferies reiterated its Buy rating on Tilray stock with a price target of $1.50 following these earnings results. The firm noted several factors contributing to the revenue shortfall, including soft beer demand and delayed cannabis shipments. Jefferies also pointed out challenges in execution and SKU cuts as reasons for the lower-than-expected sales. These developments highlight the ongoing challenges and opportunities for Tilray in the current market environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.